Haleon PLC Sponsored ADR (HLN)
(Delayed Data from NYSE)
$9.68 USD
-0.12 (-1.22%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $9.68 0.00 (0.00%) 5:50 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.68 USD
-0.12 (-1.22%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $9.68 0.00 (0.00%) 5:50 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.
HLN vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HLN vs. LMAT: Which Stock Is the Better Value Option?
Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?
by Zacks Equity Research
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates make the stock attractive
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
by Zacks Equity Research
Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
by Zacks Equity Research
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%
by Zacks Equity Research
Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.
AHCO vs. HLN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. HLN: Which Stock Is the Better Value Option?
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD
by Zacks Equity Research
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates are expected drive the stock in the future quarters.
HLN vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HLN vs. ABT: Which Stock Is the Better Value Option?
HLN vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HLN vs. SYK: Which Stock Is the Better Value Option?
HLN or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HLN vs. SYK: Which Stock Is the Better Value Option?
HLN or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HLN vs. SYK: Which Stock Is the Better Value Option?
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
by Zacks Equity Research
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
by Zacks Equity Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
by Zacks Equity Research
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
by Zacks Equity Research
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).